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Abstract
Background: Local tumor control by standard fractionated radiotherapy (RT) remains poor because of tumor
resistance to radiation (radioresistance). It has been suggested that cancer stem cells (CSCs) are more radioresistant
than non-CSCs. In previous studies, we have shown IL-6 promotes self-renewal of CD133+ CSC-like cells. In this
study, we investigated whether IL-6 plays roles not only in promoting self-renewal of CD133+ cells after radiation,
but also in conferring radioresistance of CD133+ cells in NSCLC.
Materials and methods: To compare radiation sensitivity of CSCs and non-CSCs, CD133+ CSC-like and CD133- cell
populations were isolated from two NSCLC cell lines, A549 and H157, by immunomagnetic separation and their
sensitivities to ionizing radiation were investigated using the clonogenic survival assay. To further study the IL-6 effect
on the radiosensitivity of CD133+ CSC-like cells, CD133+ cells were isolated from A549IL-6si/sc and H157IL-6si/sc cells
whose intracellular IL-6 levels were manipulated via the lentiviral transduction with IL-6siRNA. Post-irradiation DNA
damage was analyzed by γ-H2AX staining and Comet assay. Molecular mechanisms by which IL-6 regulates the
molecules associated with DNA repair and anti-apoptosis after radiation were analyzed by Western blot and
immunofluoresecence (IF) staining analyses.
Results: NSCLC CD133+ CSC-like cells were enriched upon radiation. Survival of NSCLC CD133+ cells after radiation
was higher than that of CD133- cells. Survival of IL-6 expressing NSC LC CD133+ cells (sc) was higher than that of IL-6
knocked-down cells (IL-6si) after radiation. IL-6 played a role in protecting NSCLC CD133+ cells from radiation-induced
DNA damage and apoptosis.
Conclusions: IL-6 signaling promotes DNA repair while protecting CD133+ CSC-like cells from apoptotic death after
radiation for lung cancer. A combined therapy of radiation and agents that inhibit IL-6 signaling (or its downstream
signaling) is suggested to reduce CSC-mediated radioresistance in lung cancer.
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Background
Lung cancer is the predominant cause of cancer death in
both men and women [1]. It is heterogeneous and histo-
logically divided into two types: small cell lung carcin-
omas (SCLCs) and non-small cell lung carcinomas
(NSCLCs), with the latter comprising 85 % of lung
cancer cases [2]. Radiotherapy (RT) is the standard pri-
mary treatment for patients diagnosed with localized
unresectable NSCLC. However, local tumor control by
standard fractionated RT remains poor primarily due to
tumor resistance to radiation.
Accumulating evidence indicates that cancer stem cells
(CSCs) exist as a very minor population in NSCLC tu-
mors [3–6]. It has been suggested by several investiga-
tors that CSCs are more radioresistant than non-CSCs.
Hittelman et al. [7] and Zhang et al. [8] showed that
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cancer cell colonies surviving radiation treatment exhib-
ited stem cell features, and Gomez-Casal et al. [9] re-
ported that NSCLC cells surviving radiation treatment
displayed CSC and epithelial-mesenchymal transition
(EMT) phenotypes. In addition, Baumann et al. [10] sug-
gested that local tumor control by RT was affected by
the number of CSCs in the tumors.
According to Hittelman et al. [7], radioresistance can
be influenced by different intrinsic and extrinsic factors,
including proliferation or quiescence, activated radiation
response mechanisms (e.g., enhanced DNA repair, up-
regulated cell cycle control, and increased free-radical
scavengers), and a surrounding microenvironment that
enhances cell survival (e.g., hypoxia and interaction with
stromal elements).
Implications of cytokines in radioresistance have been
suggested. Liu et al. [11] reported that the IL-6 class
cytokine leukemia inhibitory factor (LIF) promoted
radioresistance of nasopharyngeal carcinoma. It was also
shown that the inhibition of IL-4 or IL-10 resulted in
sensitization of colorectal cancer cells to radiation [12].
In addition, Zhou et al. [13] suggested that cytokines can
shift the balance between tumor cells and tumor micro-
environment after irradiation.
Our laboratory recently found that IL-6 played a pro-
moter role in the self-renewal of CD133+, CSC-like
cells in A549 and H157 cell lines, not in CD133- cells
(manuscript submitted), demonstrating that it may pro-
mote growth of the surviving CD133+ CSC-like cells
after radiation. We further investigated whether IL-6
plays roles not only in promoting self-renewal of
CD133+ cells, but also in conferring radioresistance of
CD133+ cells in NSCLC.
Methods
Cell culture
A549 and H157 cell lines were purchased from the
American Type Culture Collection (ATCC, Manassas,
VA) and cultured in RPMI 1640 containing 10 % FBS.
CD133+ CSCs were cultured in DMEM/F12 medium
supplemented with 20 ng/ml EGF (Invitrogen), and
20 ng/ml FGF (Invitrogen). All cells were maintained in
a humidified 5 % CO2 environment at 37 °C.
Flow cytometric analysis of CD133+ cells after radiation
A549 and H157 cell lines were irradiated with 6 Gy Cs-
137 gamma rays and then grown as a monolayer culture
for 7 days. After 7 days, the percentage of CD133+
population (CD133+ positively stained cells) in the cul-
ture was determined by flow cytometric analysis using
the Canto II system (Becton-Dickinson, San Antonio,
TX). The non-irradiated cells were used as control.
Development of IL-6 knocked down and sc control cells
by lentiviral transduction
For incorporation of IL-6 siRNA or scramble (sc) control
plasmids into A549 and H157 cells, lentivirus construct
carrying either sc or IL-6 siRNA (pLenti-II vector,
Applied Biological Materials Inc, Canada) was trans-
fected into 293 T cells with a mixture of pLent-II-IL-6
siRNA, psPAX2 (virus-packaging plasmid), and pMD2G
(envelope plasmid) (4:3:2 ratio) using PolyFect Transfec-
tion reagent (Qiagen, Valencia, CA). After A549 and H157
cells were infected with virus overnight, the culture media
containing the virus were removed and the infected cells
were then maintained under normal cell culture media.
After sub-culturing, the IL-6 knocked down cells were se-
lected by puromycin (2 μg/ml) (Sigma) and then main-
tained in media containing 0.1 μg/ml puromycin.
Isolation of CD133+ CSC-like cells using immunomagnetic
separation techniques
Cells (2 × 107) were detached from tissue culture plates
with 5 mM EDTA, centrifuged, and incubated with mag-
netic microbeads conjugated with anti-CD133 antibody
(Miltenyi Biotec, Cambridge, MA). The bead-bound cells
(CD133+) and unbound cells (CD133-) were separated
using the Quadro MACSTM Separation Unit (Miltenyi
Biotec, Cambridge, MA). The purity of isolated CD133+
cells was confirmed by flow cytometric analyses, and by
qPCR analyses. The isolated CD133+ cells were then
cultured in stem cell media.
Sphere formation assay
For sphere formation assays, single-cell suspensions (1 ×
103 cells) were mixed with cold Matrigel (BD, Franklin
Lakes) (1:1 ratio, v/v, total volume of 100 μl)) and the mix-
ture was placed along the rim of the 24-well plates. The
culture plates were placed in 37 °C incubator for 10 min
to let the mixture solidify, and 500 μl medium was then
added into the wells. The number of spheres with diam-
eter greater than 50 μm was counted 7–14 days later using
an Olympus light microscope. A minimum of three tripli-
cate experiments were performed.
Cell survival assay after radiation
Cells were exposed to different doses (0, 1, 2, 4, 6,
and 8 Gy) of radiation using a Cs-137 source with a
dose rate of 180–205 cGy/min. After treatment, clo-
nogenic assay was performed as previously described
[14]. Cells were seeded in culture dishes with appro-
priate dilutions to form colonies after 7–9 days incu-
bation. Colonies were fixed with methanol, stained
with crystal violet (0.5 % w/v), and counted using a
microscope. Colonies consisting of at least 50 cells
were counted and the surviving fraction was calcu-
lated from the normalized plating efficiency.
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RNA Extraction and Quantitative Real-Time PCR (qPCR)
Analysis
Total RNAs were isolated using Trizol reagent (Invitrogen).
One μg of total RNA was subjected to reverse transcription
using Superscript III transcriptase (Invitrogen). qPCR was
conducted using the appropriate primers and the Bio-Rad
CFX96 system. SYBR green was used to determine the ex-
pression levels of mRNA from genes of interest. Expression
levels were normalized to GAPDH level.
IL-6 ELISA
IL-6 in the supernatant of unseparated parental or iso-
lated CD133- and CD133+ cells of A549IL-6si/sc and
H157IL-6si/sc pairs was determined by the ELISA kit ac-
cording to the manufacturer’s instructions (BD, Franklin
Lakes). The secreted IL-6 level was normalized by cell
number.
Western blot analysis
Cells were lysed in RIPA buffer (50 mM Tris-Cl at pH 7.5,
150 mM NaCl, 1 % NP-40, 0.5 % sodium deoxycholate,
1 mM EDTA, 1 μg/mL leupeptin, 1 μg/mL aprotinin,
0.2 mM PMSF) and proteins (20–40 μg) were isolated and
separated on 8–10 % SDS/PAGE gel and then transferred
onto PVDF membranes (Millipore, Billerica, MA). After
blocking procedure, membranes were incubated with pri-
mary antibodies, followed by HRP-conjugated secondary
antibodies, and then the proteins of interest were visual-
ized using the Imager (Bio-Rad) and ECL (Thermo Fisher
Scientific, Rochester, NY) system. Antibody of GAPDH
was purchased from Abcam (Cambridge, MA) and anti-
bodies of Mcl-1and cleaved caspase-3 were obtained from
Cell Signaling (Danvers, MA). Bcl-2 antibody was ob-
tained from Santa Cruz (Santa Cruz, CA).
Immunofluoresence (IF) staining
Unseparated parental or isolated CD133- and CD133+
cells of A549IL-6si/sc and H157IL-6si/sc pairs (1 x
103) were mounted on chamber slide, irradiated
(6 Gy, with non-irradiated cells as control), and
stained with appropriate primary antibodies. Anti-
bodies of ATM and CHK2 were obtained from Bethyl
Laboratory (Montgomery, TX), phosphorylated ATM
(Ser 1981), and phosphorylated p53 (Ser 20) were
from Gene Tex (Irvine CA), and γ-H2AX antibody
was purchased from Trevigen (Gaithersburg, MD).
Antibodies of Mcl-1 and Bcl-2 were obtained from
Cell Signaling (Danvers, MA) and Santa Cruz (Santa
Cruz, CA), respectively. After reaction with Alexa
flour® 488 anti-goat secondary antibody (Life Technologies,
Grand Island, NY), images were recorded using a fluores-
cent microscope (Zeiss, Germany).
Comet assay
Isolated CD133+ and CD133- cells of IL-6si/sc pairs
were irradiated (6 Gy) and at 0 and 30 min after radi-
ation cells were used in the assay following the proced-
ure of Singh et al. [15] with some modifications. Briefly,
cells were embedded in low-melting-point agarose in
lysis buffer (10 mM Tris–HCl, pH 10, 2.5 M NaCl,
100 mM EDTA, 10 % DMSO, 1 % Triton X-100). The
unwinding step was performed for 20 min at 4 °C in un-
winding/electrophoresis buffer (300 mM NaOH, 1 mM
EDTA, pH = 13). Electrophoresis was performed at 4 °C
for 20 min in unwinding/electrophoresis buffer at elec-
tric field strength of 25 V and a current of 300 mA. The
slides were then neutralized with a neutralizing buffer
(0.4 Tris–HCl, pH 7.5) for 20 min, rinsed with distilled
water, air-dried, stained with 30 μg/ml ethidium brom-
ide. Images were recorded using a fluorescent micro-
scope (Zeiss, Germany).
ATM-luciferase assay
293HEK and H1299 cells in 24 well plates were trans-
fected with 2 μg/mL ATM reporter plasmid (Addgene,
Cambridge, MA) and 0.02 μg/mL phRL-cytomegalovirus
Renilla luciferase plasmid (used as control for normaliz-
ing transfection efficiencies) using Polyfect (Qiagen,
Valencia, CA). After transfection, cells were incubated
with or without IL-6. Twenty-four hours later, luciferase
activities were measured using the Dual-Luciferase
Reporter Assay System (Promega, Madison Wisconsin)
according to manufacturer’s instructions. Luciferase activ-
ity was measured using theGloMax® 20/20 luminometer
(Promega, Madison, WI). For data analysis, the experi-
mental reporter was normalized to the level of constitutive
reporter to adjust for the differences in transfection
efficiency.
Statistics
The data were presented as the mean ± SEM. Differences
in mean values between two groups were analyzed by
two-tailed Student’s t test. p ≤ 0.05 was considered statis-
tically significant.
Results
CD133+, CSC-like cells were enriched in A549 and H157
cell cultures upon exposure to radiation
To investigate whether the population of CSCs in
NSCLC was altered after radiation, unseparated A549
and H157 parental cells were irradiated with 6 Gy
gamma rays and the percentage of CD133+ cells, before
and after radiation, was analyzed by flow cytometry. The
CD133 molecule was chosen because it is the most widely
used surface marker for the CSC of NSCLC [4, 6]. As
shown in Fig. 1a, the percentage of CD133+ cells was in-
creased by 3.4 and 4.0 fold at 7 days after irradiation for
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A549 and H157 cells, respectively. Consistent with the
CD133+ population data (Fig. 1a) and the published result
by others [9], we also observed a higher number of
spheres in the sphere formation assay (Fig. 1b) and ex-
pression of CSC markers in NSCLC cell lines following ir-
radiation in IF staining (Fig. 1c).
CD133+, CSC-like cells were more resistant to radiation
than CD133- cells
Emerging evidence suggests that CSCs are likely to be
more resistant to radiation than non-CSCs [7–10, 16]. To
directly compare the radiation sensitivity of CSC and non-
CSC cells in NSCLC, we isolated CD133+ and CD133-
cells from A549 and H157 cells by anti-CD133 antibody
and the immunomagnetic separation method. Flow cyto-
metric analyses indicated an enrichment of CD133+ cells
after separation with a purity of CD133+ greater than
90 % (Fig. 2a). In order to confirm the CSC-like character-
istics of the isolated CD133+ cells, we analyzed expression
of CSC markers in these cells and in parental cells. The re-
sults showed a dramatic increase in CSC markers in
CD133+ cells (Fig. 2b, A549 cells). The CD133+ cells were
able to grow into spheres using the Matrigel-based sphere
formation assay (Fig. 2c), further indicating the isolated
CD133+ cells have CSC-like features. The CD133+ cells
were maintained under non-adherent culture conditions
with stem cell media, and the freshly isolated cells and
once passaged cells were used in the entire study.
Radiation sensitivity was determined and compared be-
tween the isolated CD133+ and CD133- cells. CD133+
and CD133- cells were isolated by an immunomagnetic
separation method one day prior to irradiation experi-
ments and the CD133+ cells were kept in stem cell media.
After irradiation to different doses of Cs-137 gamma rays,
cells were harvested, trypsinized (in case of CD133- cells),
cell numbers counted, and single cell suspensions of indi-
cated numbers of CD133- and CD133+ cells were used in
clonogenic assay at 7–9 days post-radiation. We found
survival of CD133+ cells was significantly higher than that
of CD133- cells in both cell lines (Fig. 2d; top, A549 cells;
bottom, H157 cells), indicating that CD133+ cells are
more radioresistant than CD133- cells.
Effects of intracellular level of IL-6 on mediating survival
of CD133+ cells upon irradiation
In investigating the role of IL-6 in the radiation sensitiv-
ity of CSCs, the A549 and H157 cells secreted a high
level of IL-6, so it was hard to observe the exogenously
Fig. 1 Effects of radiation on the enrichment of CD133+ populations in A549 and H157 human lung cancer cell cultures. a Percentage of CD133+ cells
was increased after radiation. Flow cytometric analysis of CD133+ cells was performed at 7 days after 6 Gy Cs-137 gamma ray irradiation (non-irradiated
cells as control). Percentage of CD133+ cells was calculated from the fluorescence distribution of anti-CD133 labeled cells. b Sphere formation
was increased in irradiated cells. A549 and H157 cells were irradiated with 6 Gy, cultured for 7 days, and then analyzed for sphere formation
(non-irradiated cells as control). Spheres with greater than 50 μm in diameter were counted at the end of incubation. *p < 0.05 c Expression of stem
cell markers was increased after radiation in IF staining. The A549 and H157 cells were seeded on chamber slides and irradiated with 6 Gy. Seven days
after irradiation, IF staining was performed using CSC marker anitbodies
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added IL-6 effect on survival of CD133+ cells after
radiation. So, we investigated the radiation survival of
CD133+ CSC-like cells obtained from parental cells whose
intracellular IL-6 level was manipulated by the IL-6 siRNA
in lentiviral transduction system. We have previously ob-
tained IL-6 knocked down A549 (A549IL-6si) and H157
(H157IL-6si) cells and their corresponding scramble (sc)
control (A549sc, H157sc) cells. The IL-6 knockdown effi-
ciency was greater than 90 % (A549) and 72 % (H157) in
qPCR analyses (Fig. 3a). The IL-6 knockdown in CD133-
and CD133+ cells are shown in ELISA test (Fig. 3b) and
IF staining (CD133+ cells, Fig. 3c). CD133+ cells were
then isolated from these A549IL-6/sc and H157IL-6si/sc
pairs and exposed to various doses of radiation for clono-
genic cell survival assay. After exposure to radiation, we
found that the survival of CD133+ cells isolated from IL-6
expressing A549sc and H157sc cells was higher than from
A549IL-6si and H157IL-6si cells (Fig. 3d), suggesting that
intracellular IL-6 is important for maintaining a greater
level of radiation survival in CD133+ cells.
We next tested whether IL-6 was also involved in
promoting the self-renewal of CD133+ cells after
Fig. 2 CD133+ cells were more radioresistant then CD133- cells. a Flow Cytometric analysis of the isolated CD133+ cells. The CD133+ cells were
isolated from A549 and H157 cells by immunomagnetic sorting using CD133+ antibody-conjugated magnetic microbeads. The isolated CD133+
cells were stained by anti-CD133+ antibody and subjected into flow cytometric analysis. The dotted and solid lines show fluorescent distributions
of unseparated and separated cell populations. Greater than 90 % purity was found in isolated CD133+ cells. b Higher expression of CSC markers
in isolated CD133+ than unseparated A549 cells. mRNA expression of the indicated CSC markers in isolated CD133+ cells were analyzed by qPCR
analyses. c Sphere formation Assay using isolated CD133+ cells of A549 and H157 cell line. d Clonogenic survival curves of CD133+ and CD133- cells.
CD133+ cells and CD133- cells of A549 and H157 cells were seeded, irradiated at different doses, and survived clone numbers at 7–9 days of
incubation were counted. The surviving fraction was obtained from normalized plating efficacies (70-75 % for CD133- cells and 30-35 % for CD133+ cells).
*p< 0.05, **p< 0.01, ***p< 0.001
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radiation. We irradiated the CD133+ cells isolated
from A549IL-6si/sc and H157IL-6si/sc pairs and per-
formed the sphere formation assay at 7 days after ir-
radiation to test their self-renewal abilities. As shown
in Fig. 3e, we observed a higher number of spheres
from A549sc and H157sc cells than those from
A549IL-6si and H157IL-6si cells. Consistent with the
spheroid formation results, a higher number of Ki67
positive cells was found in CD133+ of A549sc cells
following radiation exposure (Fig. 3f ), indicating
higher proliferating activity of IL-6 expressing CD133
+ cells.The secreted IL-6 level differences in CD133+
and CD133- cells of A549IL-6si/sc and H157IL-6si/sc
pairs are shown in Fig. 3g.
Fig. 3 IL-6 expressing CD133+ cells (sc) were more radioresistant than IL-6 knocked down (IL-6si) cells. a Confirmation of IL-6 knockdown in
IL-6si cells. IL-6 mRNA levels in A549IL-6si/sc and H157IL-6si/sc cell lines were analyzed by qPCR analyses and relative mRNA expressions were
shown. b IL-6 secreted levels in CD133+ and CD133- cells of A549IL-6si/sc and H157IL-6si/sc cell lines. Supernatants were collected from CD133-
and CD133+ cells of A549IL-6si/sc and H157IL-6si/sc cell lines and secreted IL-6 levels were analyzed by ELISA kit. c IL-6 IF staining. CD133+ cells
of A549IL-6si/sc pairs were plated and IF staining was performed using anti-IL-6 Ab. d Clonogenic survival curves showed IL-6 expressing (sc)
CD133+ cells (sc) were more radiation resistant than IL-6 knocked down (IL-6si) CD133+ cells. CD133+ cells of A549IL-6si/sc and H157IL-6si/sc
pairs were exposed to different doses of radiation. Nine days later, cell survival was analyzed by clonogenic assay. Upper panel, result of CD133+
cells of A549IL-6si/sc pair; lower panel, result of CD133+ cells of H157IL-6si/sc pair (40-50 % plating efficiencies). c Sphere formation was higher in
IL-6 expressing cells. CD133+ cells of A549IL-6si/sc and H157IL-6si/sc pairs were irradiated with 6 gamma rays. Ten days after irradiation, sphere
formation assays were performed. Spheres having diameter greater than 50 μm were counted. d Higher number of Ki67 positive cells in IL-6
expressing cultures in IF staining. CD133+ cells of A549IL-6si/sc pair were irradiated (6 Gy). Two days after irradiation, IF staining was performed
using anti-Ki67 Ab. *p < 0.05, **p < 0.01, ***p < 0.001. e Sphere formation was higher in IL-6 expressing cells. CD133+ cells of A549-6si/sc and
H157IL-6si/sc pairs were irradiated with 6Gy gamma rays. Ten days after irradiation, sphere formation assays were performed. Spheres having a
diameter greater than 50um were counted. f Higher number of Ki67 positive cells in IL-6 expressing cultures in IF staining. CD133+ cells of
A549IL-6si/sc pair were irradiated (6Gy). Two days after irradiation, IF staining was performed using anti-Ki67 Ab. g IL-6 ELISA tests of CD133- and
CD133+ cells of A549IL-6si/sc and H157IL-6si/sc pair. *p < 0.05, **p < 0.01, ***p < 0.001
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IL-6 was important in mediating DNA repair and
protecting cells from apoptotic death in CD133+ cells
after radiation damage
We then investigated whether DNA damage and repair
system in CD133+ cells was affected by IL-6 signaling
following irradiation. We irradiated CD133+ cells iso-
lated from A549IL-6si/sc and H157IL-6si/sc pairs and
performed the IF staining of γ-H2AX after irradiation.
As shown in Fig. 4a, we detected higher levels of γ-
H2AX staining in A549IL-6si and H157IL-6si cells, indicat-
ing greater amount of DNA damage still left unrepaired
when IL-6 was knocked down in CD133+ cells. Different
levels of post-irradiation DNA strand breaks in CD133-
and CD133+ cells of A549IL-6si/sc and H157IL-6si/sc pairs
were also investigated in the Comet assay. When CD133-
and CD133+ cells were isolated from A549IL-6si/sc and
Fig. 4 IL-6 knocked down CD133+ cells showed lower expression of DNA repair-associated molecules. a Higher expression of γ-H2AX indicating
unrepaired DNA damage was found in IL-6 knocked down CD133+ cell cultures measured by IF staining. CD133+ cells of A549IL-6si/sc and
H157IL-6si/sc pairs were irradiated with 6 Gy gamma rays and γ-H2AX IF staining was performed at 3 h after irradiation. b Higher DNA strand
breaks were detected in CD133+ cells of IL-6si cells than those of sc cells. CD133+ and CD133- cells were obtained from A549IL-6si/sc and
H157IL-6si/sc cell pairs, irradiated (6 Gy), and DNA strand breaks were analyzed at 0 and 30 min after radiation in Comet assay. The ratio of head
diameter to comet length of 50 cells were measured in each sample analysis and used in quantitation shown on right. c Lower expression of
DNA repair associated proteins, ATM, CHK2, p-ATM, and p-p53 were detected in CD133+ cells of IL-6 knocked down cell line than those of sc
counterparts (IF staining). CD133+ and CD133- cells of A549IL-6si/sc and H157IL-6si/sc pairs were irradiated with 6 Gy gamma rays and IF staining
was performed at 2 h after irradiation using antibodies of ATM, CHK2, p-ATM, and p-p53. d qPCR analysis. CD133+ cells of A549IL-6si/sc and
H157IL-6si/sc pairs were irradiated with 6 Gy gamma rays and total RNAs were obtained for qPCR analyses at 6 h after irradiation. e ATM-luc assay.
293HEK and H1299 cells were transfected with ATM-luc and cultured with various concentrations of IL-6. At the end of 48 h of incubation, luciferase
activities were measured
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H157IL-6si/sc pairs and irradiated at 6 Gy, we detected a
similar extent of DNA damage in the CD133- and CD133+
cells of IL-6si/sc pair immediately after radiation, but lower
DNA breaks in CD133+ cells of IL-6sc cell lines than those
of IL-6si cell lines were detected at 30 min after radiation
(Fig. 4b), suggesting higher DNA repair in CD133+ cells of
IL-6sc cell lines than those of IL-6si cell lines. However, we
did not observe a significant difference in DNA repair in
CD133- cells of A549IL-6si/sc and H157IL-6si/sc pairs.
We then investigated whether the higher level of unre-
paired DNA damage in IL-6 knocked down cells was due
to lower DNA repair activity. We investigated expression
of ATM [17] and its downstream molecules, including
ATM, phosphorylated ATM, CHK2, and phosphorylated
p53, in CD133- and CD133+ cells of A549IL-6si/sc and
H157IL-6si/sc cell pairs upon radiation. The results of IF
staining showed that the CD133+ cells from A549IL-6si
and H157IL-6si cell lines exhibited lower expression of
these molecules than those isolated from sc cell lines
(Fig. 4c). However, not much difference was observed in
CD133- cells, whether isolated from IL-6si or sc cell lines.
To further explore whether the ATM and CHK2 are
up-regulated in IL-6 expression CD133+ cells after radi-
ation, we compared the mRNA levels of ATM and
CHK2 in A549IL-6si/sc and H157IL-6si/sc pairs follow-
ing radiation exposure. Similar to the IF staining results,
higher levels of ATM mRNA were observed in the IL-6
expressing and CD133+ sc cells compared to those of
IL-6 knocked down cells (Fig. 4d).
Next, we investigated whether IL-6 regulates ATM at
the transcriptional level in the 293HEK cell line using
the ATM-luciferase constructs containing the ATM pro-
moter region. We also used non-IL-6 expressing H1299
NSCLC cell line in this assay to observe the exogenously
added IL-6 effect. We detected a dose dependent regula-
tion of ATM-luciferase by IL-6 in these two cell lines,
suggesting direct regulation of IL-6 on ATM molecule at
the transcriptional level (Fig. 4e).
We then investigated whether difference in expression
of apoptosis markers could be detected between IL-6 ex-
pressing (sc) and knocked down (IL-6si) CD133+ cells. As
shown in Fig. 5a, we observed a higher level of cleaved
caspase in A549IL-6si cells than A549sc cells, indicating
more apoptosis in IL-6 knocked down cells following radi-
ation. When we examined expression of anti-apoptotic
markers Bcl-2 and Mcl-1 in the A549IL-6si/sc cell line
pair, higher expression of these molecules in IL-6 express-
ing CD133+ cells were observed in Western blot (Fig. 5a)
and IF staining (Fig. 5b) analyses. These results suggest
that IL-6 in CD133+ cells modulated up-regulations of
these molecules, and protected cells from apoptotic death
upon irradiation.
In summary, [1] NSCLC CD133+ CSC-like cells were
enriched upon radiation, [2] cell survival of NSCLC
CD133+ cells after radiation was higher than that of
CD133- cells, [3] cell survival of IL-6 expressing NCSLC
CD133+ cells (sc) was higher than that of IL-6 knocked-
down cells (IL-6si) after radiation [4] IL-6 played a role
in protecting NSCLC CD133+ cells from radiation-
induced DNA damage and apoptosis.
Discussion
We first demonstrated that CD133+ CSC-like cells were
enriched after radiation in NSCLC cells. This result is
consistent with previous reports by Desai et al. [18]
showing an increase of CSC in A549 cell line after radi-
ation, and by Gomez-Casal [9] showing an expansion of
sphere numbers and increase of CSC marker expression
after radiation.
We then investigated the survival of CSCs and non-
CSCs upon radiation since a direct comparison showing
the difference between CSC and non-CSC originated
from same lung cancer cell line has not been studied be-
fore. Our in vitro cell survival results clearly demon-
strated that the CD133+ cells had higher survival than
CD133- cells after radiation (Fig. 2), which is clear evi-
dence suggesting that CSCs are more radioresistant than
non-CSCs.
Regarding the molecular mechanisms by which CSCs
exhibit higher radioresistance than non-CSCs, Pajonk et
al. [19] suggested that the CSC is inherently radioresis-
tant. Matthews et al. [20] proposed that CSC has higher
expression of radioresistance-related genes and higher
DNA repair ability. However, it is widely accepted that
the other factors such as adaptive responses in CSC and
microenvironmental changes upon irradiation can con-
tribute to radioresistance in CSCs [21]. Bao et al. [22]
showed that glioma stem cells promote radioresistance
by preferential activation of the DNA damage response.
In addition, several signaling pathways were suggested to
be involved in radioresistance of CSCs. Piao et al. [16]
showed increased activation of MAPK/PI3K signaling
pathway and reduction in reactive oxygen species levels
in CD133+ cells of human hepatocarcinoma compared
to CD133- cells upon irradiation. Meanwhile, Ettl et al.
[23] showed AKT and MET signaling mediates anti-
apoptotic radioresistance in head neck cancer cell lines,
and Kim et al. [24] suggested that EZH2 is important in
radioresistance of CSC in glioblastoma.
In this study, we suggest that IL-6 signaling may be
important in promoting radioresistance in NSCLC
CD133+ cells. We speculate that intracellular IL-6 may
be more critical in protecting cells from radiation-
induced damage since we observed higher radioresis-
tance of sc cells compared to IL-6si cells, but could not
detect significant effect when IL-6 was added exogen-
ously to the non-IL-6 expressing H1299 cells. Contribu-
tion of IL-6 in radioprotection has been suggested
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previously. In animal studies, Neta et al. [25] showed re-
duced mortality upon irradiation when mice were pre-
treated with IL-6 antibody. In addition, Wu et al. [26]
showed that IL-6 plays a role in radioresistance of cas-
tration resistant prostate cancer. However, no clear IL-6
role had been addressed in protection of NSCLC CSCs
from radiation. In our study, we clearly demonstrated
the IL-6 role in mediating radioresistance of NSCLC
CD133+ cells.
We suggested that the effect of IL-6 in mediating
radioresistance is partially arbitrated through regulation
of DNA repair related molecules. Desai et al. [18] also
suggested that the radioresistance in CD133+ cells is
gone through DNA repair molecules, such as Exo1 and
Rad51. Using several different assays, we showed the
regulation of IL-6 on the key molecules of DNA repair,
ATM and CHK, in CD133+ cells. This result is consist-
ent with the recent observation showing IL-6 regulation
of ATM/NFkB signaling in conferring the resistance of
lung cancer to chemotherapy [27]. Although we have
only studied IL-6 regulation on ATM and CHK, identify-
ing the IL-6 effect on regulation of other DNA repair as-
sociated molecules will be carried out in future studies.
In this study, we showed that IL-6 may modulate
ATM and CHK at the transcriptional level. However, it
may also be possible that the IL-6 effect can go through
signaling pathways which is downstream of IL-6 signal-
ing as the ATM level was suggested to be modulated by
signaling pathways, such as Akt and Erk [28]. Therefore,
whether IL-6 regulates their activation by mediating up-
regulation of these molecules should be tested.
In addition to the modulation of DNA repair mechan-
ism, we showed that IL-6 regulated expression of anti-
apoptotic proteins Bcl-2 and Mcl-1. The IL-6 regulation
of Bcl-2 and Mcl-1 in CD133+ cells, without the radi-
ation effect, has been shown in our previous studies
(manuscript submitted). Whether this regulation can be
accelerated after radiation will be tested.
Fig. 5 IL-6 knocked down CD133+ cells showed lower expression of anti-apoptosis associated molecules. a Western blot analysis of apoptosis
associated proteins. CD133+ cells of A549IL-6si/sc and H157IL-6si/sc pairs were irradiated with 6 Gy gamma rays. Two days after irradiation, cell
extracts were obtained and expression of Bcl-2 and Mcl-1 were examined by Western blot analyses. b IF staining of Bcl-2 and Mcl-1. CD133+ cells
of A549IL-6si/sc and H157IL-6si/sc pairs were plated in chamber slides and irradiated with 6 Gy gamma rays. Two days after irradiation, IF staining
was performed using antibodies of Bcl-2 and Mcl-1. *p < 0.05, **p < 0.01
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Conclusions
Our data suggest that IL-6 contributes to radioresistance
of CD133+ CSC-like cells in NSCLC by protecting them
against radiation-induced DNA damage and apoptotic
death. In light of the high recurrence rate of NSCLC
after RT, and considering CSC as the target population
with high radioresistance, we suggest a combination of
radiation and agents that inhibit IL-6 signaling (or its
downstream signaling) to reduce CSC-mediated radiore-
sistance in lung cancer.
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